Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
Open Access
- 9 October 2018
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 9 (6) , 2325-2334
Abstract
Insulin glargine 300 U/mL (Gla-300, Toujeo®) is a long-acting, once-daily basal insulin with improved—more stable and smoother—pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). These properties have been shown to translate into an effective HbA1c reduction with the advantage of a lower risk of hypoglycemia in randomized controlled trials of Gla-300 versus Gla-100. In this study, we assessed the effectiveness and safety of Gla-300 under real-world conditions in Switzerland.Keywords
This publication has 26 references indexed in Scilit:
- Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United KingdomCurrent Medical Research and Opinion, 2016
- Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulinDiabetes, Obesity and Metabolism, 2016
- Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extensionDiabetes, Obesity and Metabolism, 2015
- Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetesDiabetes, Obesity and Metabolism, 2014
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)Diabetes Care, 2014
- New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1Diabetes Care, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Clinical Inertia in People With Type 2 DiabetesDiabetes Care, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetic Medicine, 2012